Brokerages expect Inogen Inc (NASDAQ:INGN) to report $62.60 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Inogen’s earnings, with the lowest sales estimate coming in at $60.89 million and the highest estimate coming in at $64.80 million. Inogen posted sales of $52.50 million in the same quarter last year, which suggests a positive year over year growth rate of 19.2%. The business is scheduled to report its next earnings report on Tuesday, May 8th.
On average, analysts expect that Inogen will report full year sales of $62.60 million for the current fiscal year, with estimates ranging from $303.00 million to $303.58 million. For the next fiscal year, analysts expect that the business will post sales of $358.58 million per share, with estimates ranging from $350.54 million to $363.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Inogen.
A number of analysts have recently issued reports on the stock. BidaskClub raised shares of Inogen from a “hold” rating to a “buy” rating in a report on Friday, March 9th. Zacks Investment Research cut shares of Inogen from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 5th. Needham & Company LLC increased their price objective on shares of Inogen from $125.00 to $150.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, February 28th. Finally, Piper Jaffray Companies upgraded shares of Inogen from a “neutral” rating to an “overweight” rating in a research note on Tuesday, February 20th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $107.29.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lenox Wealth Advisors Inc. bought a new stake in Inogen during the 4th quarter worth approximately $100,000. Steward Partners Investment Advisory LLC raised its stake in Inogen by 1,000.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock worth $130,000 after acquiring an additional 1,000 shares during the period. Simplex Trading LLC bought a new stake in Inogen during the 4th quarter worth approximately $153,000. LS Investment Advisors LLC raised its stake in Inogen by 138.6% during the 4th quarter. LS Investment Advisors LLC now owns 1,515 shares of the medical technology company’s stock worth $180,000 after acquiring an additional 880 shares during the period. Finally, Everence Capital Management Inc. bought a new stake in Inogen during the 4th quarter worth approximately $208,000. Institutional investors own 99.46% of the company’s stock.
Shares of Inogen (INGN) opened at $127.35 on Wednesday. The stock has a market cap of $2,646.60, a PE ratio of 134.05, a PEG ratio of 3.49 and a beta of 1.03. Inogen has a 1-year low of $73.05 and a 1-year high of $134.97.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://weekherald.com/2018/03/14/zacks-analysts-expect-inogen-inc-ingn-will-post-quarterly-sales-of-62-60-million.html.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.